Dr. William Williams reports

BRIACELL OPENS FIRST CANADIAN SITE – SUNNYBROOK – FOR PIVOTAL PHASE 3 TRIAL IN METASTATIC BREAST CANCER

The Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ont., Canada, has joined Briacell Therapeutics Corp.'s continuing pivotal phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.

• Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins Briacell's pivotal phase 3 clinical trial in metastatic breast cancer.
• Briacell phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026."

In the United States, Briacell's phase 3 study now has over 80 active clinical sites across 15 states, including Penn Medicine's Abramson Cancer Center, Mayo Clinic, Smilow Cancer Hospital at Yale New Haven, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Sylvester Comprehensive Cancer Center (University of Miami), Texas Oncology-Baylor Charles A. Sammons Cancer Center and the University of Arizona.

"There are a limited number of effective treatment options for patients with metastatic breast cancer and, unfortunately for most patients, standard treatments eventually stop working," commented Katarzyna Jerzak, MD, MSc, FRCPC, medical oncologist and clinician investigator at Sunnybrook's Odette Cancer Centre, and associate professor in the Department of Medicine, University of Toronto. "We are excited to evaluate Briacell's innovative immunotherapy approach and to offer these patients the opportunity to access a potentially effective new treatment."

"Opening our first Canadian clinical site for Briacell's pivotal phase 3 study is an important milestone," stated Dr. William V. Williams, Briacell's president and chief executive officer. "Sunnybrook is a world-class cancer centre, and its participation expands access to our Bria-IMT regimen to patients in Canada, as we work to accelerate development of this our novel immunotherapy for patients with metastatic breast cancer."

Briacell's pivotal phase 3 clinical study is evaluating Briacell's lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor (CPI), compared with physician's treatment of physician's choice in patients with advanced metastatic breast cancer (the Bria-ABC study). The study's primary end point is overall survival (OS). An interim analysis is planned after 144 patient deaths have occurred, comparing mortality in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice.

Briacell recently received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the phase 3 study in metastatic breast cancer. At ASCO 2026, Briacell reported positive phase 2 survival data in a similar metastatic breast cancer patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA (Food and Drug Administration) fast-track designation.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.